gdc-0084
Small moleculeexperimental
Clinical trial activity
12 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01547546)
Timeline
Indications
Mechanism of action
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
Thought to be a dual PI3K/mTOR inhibitor but no binding/selectivity/assay data found for any of the targets.
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12- Mol. weight
- 382.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3813842 ↗
- ChEMBLCHEMBL3545324 ↗
Also known as
- gdc-0084
- gdc-0084
- gdc-0084
- rg-7666
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07287202 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2026 | SoVarGen Co., Ltd. |
| NCT06208657 | Phase 1/Phase 2 (Phase 2) | Jul 10, 2024 | Australian & New Zealand Childhood Hematology & Oncology Group, Bristol-Myers Squibb, C17 Council, Day One Biopharmaceuticals, Inc., Kazia Therapeutics Limited, Medical Research Future Fund (MRFF), Stand Up To Cancer, University of Toronto |
| NCT05183204 | Phase 2 | Feb 14, 2022 | Cornell University, Kazia Therapeutics Limited |
| NCT05009992 | Phase 2 | Oct 20, 2021 | Mithil Prasad Foundation, Storm the Heavens Fund, The Chad-Tough Defeat DIPG Foundation, University of California, San Francisco |
| NCT05012670 | Phase 1 | Aug 18, 2021 | Kazia Therapeutics Limited, Quotient |
| NCT04906096 | Phase 2 | Jun 1, 2021 | Harvard University, Kazia Therapeutics Limited |
| NCT04192981 | Phase 1 | Dec 6, 2019 | Kazia Therapeutics Limited, Memorial Sloan-Kettering Cancer Center |
| NCT03994796 | Phase 2 | Jul 31, 2019 | Genentech, Harvard University, National Cancer Institute (NCI) |
| NCT03765983 | Phase 2 | Feb 11, 2019 | Harvard University, Kazia Therapeutics Limited |
| NCT03696355 | Phase 1 | Nov 19, 2018 | Kazia Therapeutics Limited, St. Jude Children's Hospital |
| NCT03522298 | Phase 2 | May 15, 2018 | Kazia Therapeutics Limited |
| NCT01547546 | Phase 1 | Apr 1, 2012 | Genentech |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (20)
20 organizations
Page 1 / 1